Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Pavlidis

Showing results (81-90 of 191) with videos related to

Pageof 20
Sort By:
Critical Reviews in Oncology/Hematology|September 11, 2018
A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma originJoseph Kattan, Elie El Rassy, Tarek Assi, et al.
Anti-Cancer Drugs|June 5, 2002
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation studyEvangelos Briasoulis, Vasilis Karavasilis, Eleftheria Tzamakou, et al.
Critical Reviews in Oncology/Hematology|February 28, 2020
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?Elie Rassy, Pauline Parent, Felix Lefort, et al.
Expert Opinion on Therapeutic Targets|July 6, 2021
Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncologyStergios Boussios, Elie Rassy, Sidrah Shah, et al.
Cancer|August 19, 2004
Metastatic breast carcinoma confined to bone: portrait of a clinical entityEvangelos Briasoulis, Vasilis Karavasilis, Lida Kostadima, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunctionEvangelos Briasoulis, Vasilis Karavasilis, Eleftheria Tzamakou, et al.
Anti-Cancer Drugs|July 22, 2010
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group StudyEvangelos Briasoulis, Vassilis Golfinopoulos, Maria Karina, et al.
Journal of the National Cancer Institute|November 16, 2006
Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatmentsMaria Kyrgiou, Georgia Salanti, Nicholas Pavlidis, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 28, 2014
Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomideEvangelia Peponi, Ioannis Tourkantonis, Ifigeneia Tasiou, et al.
Annals of Translational Medicine|January 25, 2021
Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answeredElie Rassy, Tarek Assi, Stergios Boussios, et al.
Pageof 20

Showing results (81-90 of 191) with videos related to

Sort By:
Pageof 20
Critical Reviews in Oncology/Hematology|September 11, 2018
A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma originJoseph Kattan, Elie El Rassy, Tarek Assi, et al.
Anti-Cancer Drugs|June 5, 2002
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation studyEvangelos Briasoulis, Vasilis Karavasilis, Eleftheria Tzamakou, et al.
Critical Reviews in Oncology/Hematology|February 28, 2020
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?Elie Rassy, Pauline Parent, Felix Lefort, et al.
Expert Opinion on Therapeutic Targets|July 6, 2021
Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncologyStergios Boussios, Elie Rassy, Sidrah Shah, et al.
Cancer|August 19, 2004
Metastatic breast carcinoma confined to bone: portrait of a clinical entityEvangelos Briasoulis, Vasilis Karavasilis, Lida Kostadima, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunctionEvangelos Briasoulis, Vasilis Karavasilis, Eleftheria Tzamakou, et al.
Anti-Cancer Drugs|July 22, 2010
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group StudyEvangelos Briasoulis, Vassilis Golfinopoulos, Maria Karina, et al.
Journal of the National Cancer Institute|November 16, 2006
Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatmentsMaria Kyrgiou, Georgia Salanti, Nicholas Pavlidis, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 28, 2014
Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomideEvangelia Peponi, Ioannis Tourkantonis, Ifigeneia Tasiou, et al.
Annals of Translational Medicine|January 25, 2021
Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answeredElie Rassy, Tarek Assi, Stergios Boussios, et al.
Pageof 20